Virus | Page 90 of 96 | SpiritIndia.com

Influenza :: Promise Against H5N1 Influenza Virus

Experiments in mice show that an antiviral drug currently used against annual influenza strains also can suppress the deadly influenza virus that has spread from birds to humans, killing dozens of people in Vietnam, Cambodia and Thailand since early 2004. This study, the first published report conducted on oseltamivir against the H5N1 influenza strain circulating in Vietnam, found that the drug, sold commercially as Tamiflu, dramatically boosted the survival rate of infected mice.

HIV :: Fixed dose combination drug product lamivudine and zidovudine tablets

The Food and Drug Administration within the U.S. Department of Health and Human Services (HHS/FDA) announced the tentative approval of the fixed-dose combination drug product lamivudine and zidovudine tablets manufactured by Aurobindo Pharma Ltd. of Hyderabad, India.

Skin Care :: SCULPTRA for facial fat loss – lipoatrophy

The U.S. Food and Drug Administration (FDA) advisory committee recently approved SCULPTRA (injectable poly-L-lactic acid) for use in correcting shape and contour deficiencies resulting from facial fat loss (lipoatrophy) in people with human immunodeficiency virus (HIV).

Smallpox :: Cancer Drug Slows Poxvirus in Mice

Mice given a relatively new cancer drug can survive an otherwise lethal dose of vaccinia virus, a relative of smallpox virus, report scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

HIV :: First Generic Nevirapine for AIDS Relief

The Food and Drug Administration (FDA) announced the tentative approval of two applications for nevirapine tablets manufactured by Ranbaxy Laboratories Limited, Guragon, India and Aurobindo Pharma Limited, Hyderabad, India. These are the first generic versions of Viramune Tablets manufactured by Boehringer Ingelheim. These products will now be available for consideration for purchase under the President?s Emergency Plan for AIDS Relief (PEPFAR).

HIV :: Efavirenz for AIDS Relief

The Food and Drug Administration (FDA) within the U.S. Department of Health and Human Services (HHS) announced the tentative approval of efavirenz tablets manufactured by Aurobindo Pharma LTD. of Hyderabad, India. This product is the first tentatively approved generic version of Sustiva Tablets (manufactured by Bristol-Myers Squibb). Efavirnez will now be available for consideration for purchase under the President’s Emergency Plan for AIDS Relief (PEPFAR).

HIV :: Aptivus – New Therapy for HIV Patients with Advanced Disease

The Food and Drug Administration (FDA) announced the approval of Aptivus (tipranavir) capsules, an HIV protease inhibitor, to be given with ritonavir for treatment of HIV-1 infected adults. This is the second drug approved for patients with advanced HIV disease, and provides a new therapy for patients with limited treatment options.

HIV :: Glaxo inks AIDS vaccine deal with non-profit group

GlaxoSmithKline Plc is to develop an experimental AIDS vaccine in collaboration with a non-profit group, in the first such public-private HIV vaccine partnership involving a major company.

HIV :: Generic Nevirapine for AIDS Relief

HIV :: Human Cells Can Silence HIV Genes – RNA silencing

For the first time, scientists have shown that humans use an immune defense process common in plants and invertebrates to battle a virus. The new finding that human cells can silence an essential part of HIV?s genetic make-up could have important implications for the treatment of people infected with the virus. Led by Kuan-Teh Jeang, M.D, Ph.D., of the National Institute of Allergy and Infectious Diseases (NIAID), part the National Institutes of Health, the researchers published their findings in this week?s issue of the journal Immunity.